Board Meeting25 May 2026, 10:01 pm

Fredun Pharma Recommends 7% Final Dividend, Bonus Issue 2:1

AI Summary

Fredun Pharmaceuticals Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of 7% (70 paise per share). The board also approved an increase in authorized share capital from ₹10 Crores to ₹50 Crores and a bonus share issue in the ratio of 2:1, subject to shareholder approval. Additionally, M/s. Nikhil Maniar & Associates and M/s. Joshi Apte & Associates were appointed as Internal Auditor and Cost Auditor, respectively, for FY 2026-27.

Key Highlights

Final dividend of 7% (70 paise per share) recommended for FY 2025-26.
Bonus share issue approved in the ratio of 2:1, subject to shareholder approval.
Authorized share capital increased from ₹10 Crores to ₹50 Crores.
Standalone and consolidated audited financial results for FY26 approved.
Internal and Cost Auditors appointed for the financial year 2026-2027.

View BSE Filing

FREDUN

Pharmaceuticals

Fredun Pharmaceuticals Ltd

Price Impact